Loading
A phase 3 trial of Anitocabtagene autoleucel, Cyclophosphamide, Fludarabine in multiple myeloma, run by Kite, A Gilead Company, active and no longer recruiting.
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT06413498 by Kite, A Gilead Company, with 452 participants enrolled, started 2024-08-23 and due to reach its primary completion in 2028-07. Interventions recorded: Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Pomalidomide, Bortezomib.
Shares Anitocabtagene autoleucel, Relapsed or refractory multiple myeloma, CAR-T cell therapy, Multiple myeloma.
Shares Hospital-made CAR-T under one shared regulatory master file, Hospital-based CAR-T manufacturing at cost through a public network, Relapsed or refractory multiple myeloma, CAR-T cell therapy.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Pomalidomide, Bortezomib, Dexamethasone, Relapsed or refractory multiple myeloma.